{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:36Z","timestamp":1787026536382,"version":"build-2736575974"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T00:00:00Z","timestamp":1541376000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006084","name":"Office of AIDS Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007936","name":"International AIDS Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007936","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02552","type":"journal-article","created":{"date-parts":[[2018,11,4]],"date-time":"2018-11-04T23:32:11Z","timestamp":1541374331000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells"],"prefix":"10.3389","volume":"9","author":[{"given":"Amanda G.","family":"Tomalka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivelisse","family":"Resto-Garay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry S.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Popkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/387188a0","article-title":"Decay characteristics of HIV-1-infected compartments during combination therapy","volume":"387","author":"Perelson","year":"1997","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.04.030","article-title":"Targeting the latent reservoir for HIV-1","author":"Sengupta","year":"2018","journal-title":"Immunity"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/nm1295-1284","article-title":"In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency","volume":"1","author":"Chun","year":"1995","journal-title":"Nat Med."},{"key":"B4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/387183a0","article-title":"Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection","volume":"387","author":"Chun","year":"1997","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"crossref","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","article-title":"Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy","volume":"94","author":"Chun","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5341.1291","article-title":"Recovery of replication-competent HIV despite prolonged suppression of plasma viremia","author":"Wong","year":"1997","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/44755","article-title":"Re-emergence of HIV after stopping therapy","volume":"401","author":"Chun","year":"1999","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"15109","DOI":"10.1073\/pnas.96.26.15109","article-title":"HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (Haart) in patients with a history of sustained viral suppression","volume":"96","author":"Davey","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"B10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV By CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"Hutter","year":"2009","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/QAD.0000000000000166","article-title":"A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells","volume":"28","author":"Yukl","year":"2014","journal-title":"AIDS"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1005535","DOI":"10.1371\/journal.ppat.1005535","article-title":"Real-time predictions of reservoir size and rebound time during antiretroviral therapy interruption trials for HIV","volume":"12","author":"Hill","year":"2016","journal-title":"PLoS Pathog."},{"key":"B13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature21710","article-title":"CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses","volume":"543","author":"Descours","year":"2017","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"eaar6759","DOI":"10.1126\/scitranslmed.aar6759","article-title":"CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells","volume":"10","author":"Abdel-Mohsen","year":"2018","journal-title":"Sci Transl Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1038\/s41467-018-05157-w","article-title":"CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir","volume":"9","author":"Badia","year":"2018","journal-title":"Nat Commun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3389\/fimmu.2018.01217","article-title":"Mass cytometry analysis reveals the landscape and dynamics of CD32a(+) CD4(+) T cells from early HIV infection to effective cart","volume":"9","author":"Coindre","year":"2018","journal-title":"Front Immunol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy461.","article-title":"The latent HIV reservoir resides primarily in CD32- CD4+ T cells in perinatally, HIV-infected adolescents with long-term virologic suppression","author":"Dhummakupt","year":"2018","journal-title":"J Infect Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e00901","DOI":"10.1128\/JVI.00901-18","article-title":"CD32(+) and PD-1(+) lymph node CD4 T cells support persistent HIV-1 transcription in treated aviremic individuals","volume":"92","author":"Noto","year":"2018","journal-title":"J Virol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/QAI.0000000000001622","article-title":"CD32 expression of different memory T cell subpopulations in the blood and lymph nodal tissue of HIV patients and healthy controls correlates with immune activation","volume":"77","author":"Wittner","year":"2018","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3389\/fimmu.2018.00928","article-title":"CD32-expressing CD4 T cells are phenotypically diverse and can contain proviral HIV DNA","volume":"9","author":"Martin","year":"2018","journal-title":"Front Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"9148","DOI":"10.1128\/JVI.01297-13","article-title":"High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects","volume":"87","author":"Iglesias-Ussel","year":"2013","journal-title":"J Virol."},{"key":"B22","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4049\/jimmunol.135.3.1624","article-title":"T cell activation via CD2 [T, Gp50] molecules: accessory cells are required to trigger T cell activation via CD2-D66 Plus CD2-9.6\/T11(1) epitopes","volume":"135","author":"Brottier","year":"1985","journal-title":"J Immunol."},{"key":"B23","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.4049\/jimmunol.140.5.1401","article-title":"Human memory T Lymphocytes express increased levels of three cell adhesion molecules (Lfa-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced ifn-gamma production","volume":"140","author":"Sanders","year":"1988","journal-title":"J Immunol."},{"key":"B24","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.4049\/jimmunol.144.5.1591","article-title":"Increases in tyrosine phosphorylation are detectable before Phospholipase C activation after T cell receptor stimulation","volume":"144","author":"June","year":"1990","journal-title":"J Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/eji.1830210828","article-title":"The tyrosine kinase activity of p56lck is increased in human T cells activated via CD2","volume":"21","author":"Danielian","year":"1991","journal-title":"Eur J Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1084\/jem.178.1.211","article-title":"Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses","volume":"178","author":"Miller","year":"1993","journal-title":"J Exp Med."},{"key":"B27","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.4049\/jimmunol.152.6.2753","article-title":"Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. structure\/function analysis in vitro and in human CD2 transgenic mice","volume":"152","author":"Majeau","year":"1994","journal-title":"J Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/00007890-199602150-00004","article-title":"Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival","volume":"61","author":"Kaplon","year":"1996","journal-title":"Transplantation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/eji.200323586","article-title":"Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells","volume":"33","author":"Cooper","year":"2003","journal-title":"Eur J Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.clindermatol.2007.10.028","article-title":"Alefacept in the treatment of Psoriasis","volume":"26","author":"Sugiyama","year":"2008","journal-title":"Clin Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/archderm.139.12.1563","article-title":"Treatment of Psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts","volume":"139","author":"Gordon","year":"2003","journal-title":"Arch Dermatol."},{"key":"B32","first-page":"117","article-title":"Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque Psoriasis","volume":"13","author":"Ortonne","year":"2003","journal-title":"Eur J Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1056\/NEJM200107263450403","article-title":"Treatment of chronic plaque psoriasis by selective targeting of memory effector T Lymphocytes","volume":"345","author":"Ellis","year":"2001","journal-title":"N Engl J Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1067\/mjd.2002.127247","article-title":"A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque Psoriasis","volume":"47","author":"Krueger","year":"2002","journal-title":"J Am Acad Dermatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1046\/j.1468-3083.17.s2.4.x","article-title":"Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque Psoriasis","volume":"17","author":"Krueger","year":"2003","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1046\/j.1365-4362.2003.01793.x","article-title":"Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy","volume":"42","author":"Lowe","year":"2003","journal-title":"Int J Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1046\/j.1468-3083.17.s2.3.x","article-title":"Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque Psoriasis","volume":"17","author":"Ortonne","year":"2003","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jim.2005.08.010","article-title":"Comparative study of NK cell-mediated cytotoxicity using radioactive and flow cytometric cytotoxicity assays","volume":"306","author":"Langhans","year":"2005","journal-title":"J Immunol Methods."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1128\/MCB.01013-13","article-title":"Negative elongation factor is required for the maintenance of proviral latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat","volume":"34","author":"Jadlowsky","year":"2014","journal-title":"Mol Cell Biol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS ONE"},{"key":"B41","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.4049\/jimmunol.180.9.6392","article-title":"Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy","volume":"180","author":"Binyamin","year":"2008","journal-title":"J Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1002\/eji.201344179","article-title":"Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity","volume":"44","author":"Anikeeva","year":"2014","journal-title":"Eur J Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1099\/0022-1317-72-9-2065","article-title":"A human monoclonal antibody against varicella-zoster virus glycoprotein III","volume":"72","author":"Sugano","year":"1991","journal-title":"J Gen Virol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1089\/aid.1992.8.553","article-title":"Functional activity of an HIV-1 neutralizing igg human monoclonal antibody: ADCC and complement-mediated lysis","volume":"8","author":"Posner","year":"1992","journal-title":"AIDS Res Hum Retroviruses."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.4049\/jimmunol.168.9.4462","article-title":"Alefacept, an immunomodulatory recombinant LFA-3\/IgG1 fusion protein, induces CD16 signaling and CD2\/CD16-dependent apoptosis of CD2(+) cells","volume":"168","author":"Da","year":"2002","journal-title":"J Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.3791\/2540","article-title":"Expansion, purification, and functional assessment of human peripheral blood NK cells","volume":"48","author":"Somanchi","year":"2011","journal-title":"J Vis Exp"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e55943","DOI":"10.1371\/journal.pone.0055943","article-title":"highly precise measurement of HIV DNA by droplet digital PCR","volume":"8","author":"Strain","year":"2013","journal-title":"PLoS ONE"},{"key":"B49","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/0092-8674(84)90039-4","article-title":"An alternative pathway of T-cell activation: a functional role for the 50 Kd T11 sheep erythrocyte receptor protein","volume":"36","author":"Meuer","year":"1984","journal-title":"Cell"},{"key":"B50","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/317428a0","article-title":"Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein","volume":"317","author":"Siliciano","year":"1985","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.4049\/jimmunol.137.5.1420","article-title":"T cell activation via CD2 [T, gp50]: the role of accessory cells in activating resting T cells via CD2","volume":"137","author":"Huet","year":"1986","journal-title":"J Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/QAD.0b013e328351f756","article-title":"HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy","volume":"26","author":"Hearps","year":"2012","journal-title":"AIDS"},{"key":"B53","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/152581601750288975","article-title":"Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92","volume":"10","author":"Maki","year":"2001","journal-title":"J Hematother Stem Cell Res."},{"key":"B54","first-page":"652","article-title":"Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells","volume":"8","author":"Gong","year":"1994","journal-title":"Leukemia"},{"key":"B55","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14653240802301872","article-title":"Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial","volume":"10","author":"Arai","year":"2008","journal-title":"Cytotherapy"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jcyt.2017.07.008","article-title":"Phase 1 clinical trial of adoptive immunotherapy using \u201coff-the-shelf\u201d activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia","volume":"19","author":"Boyiadzis","year":"2017","journal-title":"Cytotherapy"},{"key":"B58","doi-asserted-by":"publisher","first-page":"89256","DOI":"10.18632\/oncotarget.19204","article-title":"A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy","volume":"8","author":"Williams","year":"2017","journal-title":"Oncotarget"},{"key":"B59","doi-asserted-by":"publisher","first-page":"86359","DOI":"10.18632\/oncotarget.13411","article-title":"An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele","volume":"7","author":"Jochems","year":"2016","journal-title":"Oncotarget"},{"key":"B60","first-page":"68","article-title":"A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood","volume":"2","author":"Klingemann","year":"1996","journal-title":"Biol Blood Marrow Transplant."},{"key":"B61","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","article-title":"Chimeric Antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity","volume":"8","author":"Zhang","year":"2017","journal-title":"Front Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"8869","DOI":"10.1073\/pnas.95.15.8869","article-title":"Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection","volume":"95","author":"Chun","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1128\/JVI.78.3.1160-1168.2004","article-title":"T-cell subsets that harbor Human Immunodeficiency Virus (HIV) in vivo: implications for HIV pathogenesis","volume":"78","author":"Brenchley","year":"2004","journal-title":"J Virol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e4987","DOI":"10.1073\/pnas.1308313110","article-title":"The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time","volume":"110","author":"Josefsson","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B66","doi-asserted-by":"publisher","first-page":"5407","DOI":"10.1038\/ncomms6407","article-title":"Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4(+) memory T cells","volume":"5","author":"Jaafoura","year":"2014","journal-title":"Nat Commun."},{"key":"B67","doi-asserted-by":"publisher","first-page":"14070","DOI":"10.1128\/JVI.01900-14","article-title":"Quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells","volume":"88","author":"Soriano-Sarabia","year":"2014","journal-title":"J Virol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1073\/pnas.94.5.1925","article-title":"The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T Lymphocytes","volume":"94","author":"Bleul","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"key":"B69","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1089\/aid.1998.14.607","article-title":"Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood","volume":"14","author":"Mo","year":"1998","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B70","doi-asserted-by":"crossref","first-page":"8273","DOI":"10.1128\/JVI.72.10.8273-8280.1998","article-title":"Naive and memory CD4 T cells differ in their susceptibilities to human immunodeficiency virus type 1 infection following CD28 costimulation: Implicatip6s for transmission and pathogenesis","volume":"72","author":"Riley","year":"1998","journal-title":"J Virol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/00042560-200106010-00002","article-title":"CCR5 and CXCR4 expression on memory and naive T cells in HIV-1 infection and response to highly active antiretroviral therapy","volume":"27","author":"Nicholson","year":"2001","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B72","doi-asserted-by":"publisher","first-page":"10229","DOI":"10.1128\/JVI.00965-06","article-title":"Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy","volume":"80","author":"Delobel","year":"2006","journal-title":"J Virol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e49526","DOI":"10.1371\/journal.pone.0049526","article-title":"High CCR5 density on central memory CD4+ T cells in acute HIV-1 infection is mostly associated with rapid disease progression","volume":"7","author":"Yang","year":"2012","journal-title":"PLoS ONE"},{"key":"B74","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jaad.2009.07.032","article-title":"The Safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque Psoriasis","volume":"62","author":"Roberts","year":"2010","journal-title":"J Am Acad Dermatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.clinthera.2016.04.032","article-title":"Correlation among hypoglycemia, glycemic variability, and C-Peptide preservation after alefacept therapy in patients with type 1 diabetes mellitus: analysis of data from the immune tolerance network T1DAl trial","volume":"38","author":"Pinckney","year":"2016","journal-title":"Clin Ther."},{"key":"B76","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1172\/JCI81722","article-title":"Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients","volume":"125","author":"Rigby","year":"2015","journal-title":"J Clin Invest."},{"key":"B77","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1016\/j.jaad.2006.05.074","article-title":"Patch-stage mycosis fungoides in remission after therapy with alefacept","volume":"58","author":"Green","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"E1005761","DOI":"10.1371\/journal.ppat.1005761","article-title":"CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during art","volume":"12","author":"Fromentin","year":"2016","journal-title":"PLoS Pathog."},{"key":"B79","doi-asserted-by":"publisher","first-page":"21865","DOI":"10.7448\/IAS.20.1.21865","article-title":"T cells with low CD2 levels express reduced restriction factors and are preferentially infected in therapy naive chronic HIV-1 patients","volume":"20","author":"Bolduan","year":"2017","journal-title":"J Int Aids Soc."},{"key":"B80","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1126\/science.3014648","article-title":"The role of mononuclear phagocytes in HTLV-III\/LAV infection","volume":"233","author":"Gartner","year":"1986","journal-title":"Science"},{"key":"B81","doi-asserted-by":"publisher","first-page":"13042","DOI":"10.1128\/JVI.77.24.13042-13052.2003","article-title":"Macrophage-tropic simian\/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages","volume":"77","author":"Igarashi","year":"2003","journal-title":"J Virol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1080\/13550280600748946","article-title":"Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues","volume":"12","author":"Churchill","year":"2006","journal-title":"J Neurovirol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.immuni.2016.02.024","article-title":"Tissue-resident macrophage ontogeny and homeostasis","volume":"44","author":"Ginhoux","year":"2016","journal-title":"Immunity"},{"key":"B84","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3389\/fimmu.2016.00397","article-title":"Targeting the brain reservoirs: toward an HIV cure","volume":"7","author":"Marban","year":"2016","journal-title":"Front Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12977-016-0323-4","article-title":"Are T cells the only HIV-1 reservoir?","volume":"13","author":"Kandathil","year":"2016","journal-title":"Retrovirology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"68","DOI":"10.20411\/pai.v1i1.100","article-title":"Defining HIV and SIV reservoirs in lymphoid tissues","volume":"1","author":"Deleage","year":"2016","journal-title":"Pathog Immun."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.celrep.2017.01.027","article-title":"Astrocytes resist HIV-1 fusion but engulf infected macrophage material","volume":"18","author":"Russell","year":"2017","journal-title":"Cell Rep."},{"key":"B88","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1517\/14740338.4.6.975","article-title":"Alefacept: a safety profile","volume":"4","author":"Scheinfeld","year":"2005","journal-title":"Expert Opin Drug Saf."},{"key":"B89","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/09546630701247955","article-title":"Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for Psoriasis","volume":"18","author":"Scheinfeld","year":"2007","journal-title":"J Dermatolog Treat."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1097\/01.TP.0000145880.38548.0D","article-title":"Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience","volume":"78","author":"Tan","year":"2004","journal-title":"Transplantation"},{"key":"B91","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S2055-6640(20)30694-4","article-title":"Alemtuzumab-induced elimination of HIV-1-infected immune cells","volume":"2","author":"Ruxrungtham","year":"2016","journal-title":"J Virus Erad."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/QAD.0000000000001413","article-title":"Alemtuzumab induction therapy in HIV-positive renal transplant recipients","volume":"31","author":"Mclean","year":"2017","journal-title":"AIDS"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1097\/QAD.0000000000001540","article-title":"Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with sezary syndrome","volume":"31","author":"Rasmussen","year":"2017","journal-title":"AIDS"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0297-z","article-title":"Graft-versus-Leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia","author":"Kanellopoulos","year":"2018","journal-title":"Bone Marrow Transplant."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02552\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:38:27Z","timestamp":1694014707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02552\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,5]]},"references-count":94,"alternative-id":["10.3389\/fimmu.2018.02552"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02552","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,5]]},"article-number":"2552"}}